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While rare diseases (RDs) are by definition of low prevalence, the total number of
patients suffering from an RD is high, and the majority of them have neurologic
manifestations, involving central, peripheral nerve, and muscle. In 2017, 24 European
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Reference Networks (ERNs), each focusing on a specific group of rare or low-prevalence
complex diseases, were formed to improve the care for patients with an RD. One
major aim is to have “the knowledge travel instead of the patient,” which has been
put into practice by the implementation of the Clinical Patient Management System
(CPMS) that enables clinicians to perform pan-European virtual consultations. The
European Reference Network for Rare Neurological Diseases (ERN-RND) provides
an infrastructure for knowledge sharing and care coordination for patients affected
by a rare neurological disease (RND) involving the most common central nervous
system pathological conditions. It covers the following disease groups: (i) Cerebellar
Ataxias and Hereditary Spastic Paraplegias; (ii) Huntington’s disease and Other Choreas;
(iii) Frontotemporal dementia; (iv) Dystonia, (non-epileptic) paroxysmal disorders, and
Neurodegeneration with Brain Iron Accumulation; (v) Leukoencephalopathies; and (vi)
Atypical Parkinsonian Syndromes. At the moment, it unites 32 expert centers and 10
affiliated partners in 21 European countries, as well as patient representatives, but will
soon cover nearly all countries of the European Union as a result of the ongoing expansion
process. Disease expert groups developed and consented on diagnostic flowcharts and
disease scales to assess the different aspects of RNDs. ERN-RND has started to discuss
diagnostically unclear patients in the CPMS, is one of four ERNs that serve as foundation
of Solve-RD, and has established an RND training and education program. The network
will facilitate trial readiness through the establishment of an ERN-RND registry with a
minimal data of all patients seen at the ERN-RND centers, thus providing a unique
overview of existing genotype-based cohorts. The overall aim of the ERNs is to improve
access for patients with RDs to quality diagnosis, care, and treatment. Based on this
objective, ERNs aremonitored by the European Commission on a regular basis to provide
transparency and reassurance to the RD community and the general public.
Keywords: rare neurological diseases, standards of care, training and education, virtual healthcare, European
reference network
INTRODUCTION
Rare Diseases in Europe—The Current
Situation and Challenges
In Europe, a disease is considered as “rare” if it affects <1 person
in 2000 (1). Although rare diseases (RDs) have–per definition–a
low prevalence, the total number of patients with an RD is high,
concerning about 3.5–5.9% of the population that equates to 263–
446 million persons affected globally at any point in time (2).
The majority of RD have neurological manifestations, involving
central, peripheral nerve andmuscle (3). Most RDs are associated
with high unmet needs due to the lack of available and effective
diagnosis and treatment measures as well as the relative lack
of research to develop such measures, at least partly due to the
low number of medical experts available for each condition and
limited financial resources. A current analysis of Orphanet has
shown that of the 5,304 diseases defined by point prevalence,
84.5% of those analyzed have a point prevalence of <1/1,000,000
(2) and can thus be characterized as ultra-rare diseases. This
means that no single European Union (EU) member state can
provide access to the best possible healthcare to its citizens in all
areas of highly specialized healthcare for RD patients on its own.
European Reference Networks for Rare
Diseases
As response to this challenge, European Reference Networks
(ERNs) were launched in 2017 by the European Union Board
of Member States as a pan-European initiative to facilitate
access to highly specialized healthcare for patients with rare or
low-prevalence complex diseases. It also aims to reinforce the
cooperation of Healthcare Providers in the field of RDs at the
European level.
ERNs are legally based on the European Directive 2011/24/EU
on patients’ rights in cross-border healthcare.
This worldwide-unique initiative resulted in 24 ERNs being
formed, involving more than 900 specialized healthcare units
from over 300 hospitals in 26 Member States (4). There are
three ERNs with a neurological focus: ERN EpiCARE1 on rare
epilepsies, Euro-NMD2 on rare neuromuscular diseases, and
European Reference Network for Rare Neurological Diseases
(ERN-RND) that will be described in more detail below.
1https://epi-care.eu/
2https://ern-euro-nmd.eu/
Frontiers in Neurology | www.frontiersin.org 2 January 2021 | Volume 11 | Article 616569
Reinhard et al. ERN Rare Neurological Diseases
Each ERN had to fulfill a number of criteria for
implementation, evaluation, and knowledge sharing, while
the respective national authorities endorsed the individual
healthcare providers to become an ERN member. For a detailed
description of the conceptual framework, see Heon-Klin (5).
The central political aim of the ERNs is that medical expertise
“travels,” and that only in a few cases (e.g., for highly specialized
interventions and for diagnostic and therapeutic measures that
are not available in the country the respective person lives in)
the patient has to travel. This marks a significant step toward
improving healthcare quality, harmonizing medical (diagnosis)
procedures, reducing access inequalities, and increasing overall
medical experience and knowledge in the whole of Europe.
In addition, the ERNs open the possibility to get sizable
cohorts of patients in the perspective of therapeutic trials and the
development of research collaborations.
Travel of Knowledge Put Into
Practice—The Clinical Patient
Management System
To improve the diagnosis and treatment of RDs in practical
terms, the European Commission has set up the Clinical
Patient Management System (CPMS3), a web-based clinical
software application, enabling secure remote multi-national and
multidisciplinary case discussions.
The CPMS can be used by healthcare professionals of all ERNs,
who can upload patient data in a structured manner following
an informed consent procedure. Clinicians from outside the
ERNs can request CPMS-based advice from ERNs on specific
patients through referring them to the nearest national ERN
healthcare provider. So far, over 40 CPMS case discussions have
been performed by ERN-RND members.
The European Reference Network for Rare
Neurological Diseases
The ERN-RND is a network of the European RND expertise
centers. At present, it has 32 full members and 10 affiliated
partners from 21 countries (a list of the actual ERN-
RND full members and affiliated partners, their countries,
and their respective areas of expertise are provided as
Supplementary Material); however, through a currently ongoing
expansion process, the ERN-RND will be including the vast
majority of EU countries by mid-2021. Thus, ERN-RND will
be the first truly pan-European rare neurological disease (RND)
network that brings together all respective European expertise
centers. Governance and activities of ERN-RND are patient
centered that is reflected by the active involvement of European
Patient Advocacy Groups (ePAGs) representatives.
The formation of ERN-RND is timely since RNDs present
a topic of continuously growing importance in neurology.
Rapid advances in clinical knowledge in recent years have been
facilitated by the emergence of genetic and other diagnostic
technologies, helping us to develop a deeper understanding of
RDs and their causes. The defined genetic etiology of the majority
3https://cpms.ern-net.eu/login/
of RNDs has, moreover, been facilitating the development of
targeted molecular therapies for RND, such as viral vector-based
gene therapy and antisense oligonucleotides.
The huge heterogeneity of RND and healthcare systems in
Europe, as well as the still limited clinical expert workforce base
for RND at a time of rapid clinical innovation, means that there
is a very real risk that significant parts of estimated more than
500,000 RND patients across Europe might not benefit from
improved diagnosis, care, and treatment opportunities.
Consequently, the objectives of the ERN-RND are
as follows:
i. To significantly increase the overall percentage of RND
patients with a confirmed (molecular) diagnosis
ii. To improve and harmonize care including neurorehabilitation
and transition of RND patients across the EU
iii. To develop, share, and implement care pathways and
guidelines for all RND groups represented in ERN-RND
iv. To create, develop, and enhance the capacity to design,
implement, and supervise RND training, education, and
capacity building activities at the level of member states and
of the network
v. To develop comprehensive and data-based European RND
cohorts to be able to deploy digital solutions, including
artificial intelligence-based tools, for diagnosis and patient-
centered integrated care, in order to better understand these
conditions and thus improve their management and help
developing and testing treatments
vi. To define the minimum quality and interoperability criteria
for RND registries allowing the exchange of data between
existing registries and the ERN-RND registry.
Building on existing mature RND European disease networks,
such as the European Huntington’s Disease Network4, the Ataxia
Study Group5, and DystoniaNet6, which have already strong
clinical collaborations, ERN-RND focuses on the following
disease groups at the moment:
1) Cerebellar Ataxias and Hereditary Spastic Paraplegias
(Coordinators: Enrico Bertini, Alfons Macaya, Caterina
Mariotti, Rebecca Schuele)
2) Huntington’s disease and Other Choreas (Coordinators:
Anne-Catherine Bachoud-Lévi, Bernhard Landwehrmeyer,
Juan Dario Ortigoza Escobar)
3) Frontotemporal dementia (Coordinators: Isabelle Leber,
Markus Otto, Rik Vandenberghe)
4) Dystonia, (non-epileptic) paroxysmal disorders, and
Neurodegeneration with Brain Iron Accumulation
(Coordinators: Tobias Bäumer, Belen Pérez Dueñas,
Giovanna Zorzi)
5) Leukoencephalopathies (Coordinators: Odile Boespflug-
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FIGURE 1 | Network and governance structure of ERN-RND.
6) Atypical Parkinsonian Syndromes (Coordinators: Thomas
Gasser, Wassilios Meissner).
ERN-RND is coordinated at the University Hospital Tübingen,
Germany, with Holm Graessner being the coordinator and
Ludger Schöls the clinical lead. An overview about the network
and governance structure of ERN-RND is given in Figure 1.
Activities of ERN-RND are coordinated based on the covered
disease groups as well as the following cross-cutting lines of work
that address the objectives:
1) RND diagnostic pathways (Coordinator: Alexandra Durr)
2) Expert RND Care Coordination (Coordinator: Marina
de Koning-Tijssen)
3) Training, education, and capacity building (Coordinator:
Maria Judit Molnar)
4) Information sharing and disease resources (Coordinator:
Holm Graessner)
5) Guidelines, pathways, and best practice (Coordinator:
Antonio Federico)
6) Registries and Research (Coordinator: Thomas Klockgether)
7) Pediatric issues (Coordinators: Juan Dario Ortigoza Escobar,
Caroline Sevin, Nicole I. Wolf)
8) Neurorehabilitation (Coordinators: Annemieke I. Buizer,
Antonio Federico, Maria Judit Molnar, Jorik Nonnekes, Lori
Renna Linton).
RND DIAGNOSTIC PATHWAYS
To improve the diagnosis of RND patients, ERN-RND has
been implementing four activities. Firstly, the visibility of
the ERN-RND expertise centers has been improved through
collaboration with Orphanet, by providing contact information
on a newly created website7 and by rolling out a comprehensive
multi-channel information campaign. Secondly, disease
knowledge documents have been created and are being provided
to the different stakeholder groups. In particular, disease expert
groups developed and consented on RND diagnostic flowcharts,
as well as on disease scales to assess the different aspects of RND.
ERN-RND recommends the use of these flowcharts and disease
scales and actively disseminates them to clinicians, national
and European professional societies, and patient organizations8.
Thirdly, ERN-RND has started to discuss patients without a
definitive diagnosis in the CPMS. Fourthly, ERN-RND has
been collaborating with the EU rare disease diagnostic research
flagship project Solve-RD (Solving the unsolved Rare Diseases9);
ERN-RND is one of four ERNs that serve as foundation
of Solve-RD.
EXPERT RND CARE COORDINATION
RND care needs and situations differ between disease groups
as well as between countries. In order to capture and assess
care needs ERN-RND can address, a care need survey has been
performed for all disease groups covered by ERN-RND across all
EU countries (6). The survey is based on a respective publication
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of RND patients that have been identified include the (i)
development of multidisciplinary teams, (ii) implementation of
educational activities to enhance recognition of RND among
healthcare professionals and in the general population, (iii)
improvement of the accessibility to standard and advanced
genetic testing and to clinical geneticists, and (iv) development
of more dedicated tertiary centers meaning more expertise in
the field.
In addition, treatment algorithms and the composition of
the multidisciplinary care team for all covered RND will be
developed and consented on. By this process and the activities
regarding diagnostic flowchart and assessment scales, ERN-RND
will help to develop a comprehensive knowledge body of RND
care standards within ERN-RND.
TRAINING, EDUCATION, AND CAPACITY
BUILDING
ERN-RND has implemented an RND training and education
program10 based on the following pillars:
1) Educational webinar series in collaboration with the European
Academy of Neurology (EAN) and the European Reference
Network for Neuromuscular Disorders (Euro-NMD).
2) Hands-on training winter and summer schools for young
neurologists past topics ranging from “Diagnostic of rare
movement disorders” to “Hereditary white matter diseases—
clinics, genetics, therapy”.
3) Short-term mobility fellowships for RND
healthcare professionals.
In particular, the webinar series has attracted a high number of
attendees both across Europe and globally and has been expanded
from topics based on disease knowledge to neurorehabilitation.
INFORMATION SHARING AND DISEASE
RESOURCES
ERN-RND aims to become the information hub for all available
information for the diseases covered by the network. Therefore,
ERN-RND collects and edits available information as well as
produces new information and knowledge. Disease knowledge,
to be included in ERN-RND disease knowledge pages, needs
to undergo an affirmation process that includes patients’
representatives as well as expert clinicians from the network.
ERN-RND reached out to 27 European national neurological
societies with regard to setting up an RND webpage on their
respective society website to increase the visibility of RNDs across
the European community of neurologists. Although this has not
yet been implemented, it is an important part of our awareness
strategy. In addition to this, the ERN-RND monthly newsletter
is sent to a varied audience including patients, patient advocates,
clinicians, and researchers in Europe to inform them about the
latest developments within the network and in the RND field in
general. All disease information is compiled on the ERN-RND
10http://www.ern-rnd.eu/education-training/
website11. Efforts are provided to multiply document access to
patients from different languages.
GUIDELINES, PATHWAYS, AND BEST
PRACTICE
Clinical practice guidelines for RD are scarce and difficult to
find (8). Therefore, ERN-RND will use the expertise of its
partners to adopt and develop clinical practice guidelines for the
diseases covered by the network. GRADE methodology12 will
be used, following the recommendations by the EAN (9, 10).
The work on European guidelines for diagnosis and treatment
of Metachromatic Leukodystrophies has recently started.
Furthermore, ERN-RND endorses or affirms the value of
existing guidelines, depending on whether an EAN equivalent
methodology was used or not. Examples are: Management of the
ataxias toward best clinical practice (11) and the International
Guidelines for the Treatment of Huntington’s Disease (12).
As a matter of fact, guideline development in RND often
struggles with the lack of systematic reviews and strong evidence.
ERN-RND actively contributes to the project of the EAN
on guidance for developing and reporting guidelines in the
field of RNDs, as well as the critical appraisal of all existing
RND guidelines.
Furthermore, in the context of the Value of Treatment
project13, ERN-RND has set up a collaboration with the
European Brain Council to assess the benefits of expertise centers
for rare neurological disorders in consideration of the quality of
care being provided and cost-effectiveness.
REGISTRIES AND RESEARCH
With the foundation of ERN-RND, a large network of potential
trial sites for RND has been formed. As the ERN-RND expertise
centers are very likely those centers that are performing and
will perform RND treatment trials in Europe, the network will
facilitate trial readiness through three activities. Firstly, it is about
to establish an ERN-RND registry that is going to comprise
minimal data of all patients seen at the ERN-RND centers.
This registry will thus provide a unique overview of existing
genotype-based cohorts. The minimal data set being used is
based on the “Set of common data elements for Rare Diseases
Registration” as recommended by the European Platform on
Rare Disease Registration14. Secondly, ERN-RND has organized
and will be organizing multi-stakeholder workshops focusing on
the different aspects of trial readiness. Thirdly, ERN-RND will
strive to support trial readiness platforms, such as ARCA and
SCA Global15, in order to help in addressing major knowledge
gaps that preclude further progress toward the development of
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PEDIATRIC ISSUES
The working group on pediatric issues has been formed
recently to specifically address the different needs of pediatric
RND. The cross-cutting pediatric issues should be addressed
(i) within ERN-RND, (ii) in collaboration with other ERNs,
and (iii) linked with the European Pediatric Neurological
Society (EPNS).
As a first step, a mapping exercise is being performed
on the specific neuropediatric expertise of the ERN-RND
centers as well as on existing pediatric scales that are used
across the disease groups to identify potential gaps. Patient
information leaflets with a focus on pediatric issues as well as
information about clinical trials should be collected and made
available on the ERN-RND website. In addition, collaboration
with the EPNS, e.g., focusing on joint training activities, has
been implemented.
NEUROREHABILITATION
As causal treatments are only scarcely available for RND,
neurorehabilitation is an important aspect in the management of
these diseases. To address this need, a specific working group has
been formed with the following goals: (i) organization of teaching
courses on neurorehabilitation of the different RNDs. As a first
step, online training webinars focusing on neurorehabilitation of
RND have been organized. (ii) Organization of national/regional
networks for RND neurorehabilitation. (iii) Guidelines
production in collaboration with EAN panels and the European
Federation for Neurorehabilitation.
As a first step, a mapping of the locally used
neurorehabilitation protocols including the evidence on
which they are based and the possibility of transfer to other
centers is underway.
MONITORING AND EVALUATION OF
ERN-RND
The overall aim of the ERNs is to improve access for patients
with RDs to quality diagnosis, care, and treatment. Based
on this objective, ERNs are monitored on a regular basis
by the European Commission to guarantee transparency and
provide reassurance of both the RD community and the
general public. Additional reasons for monitoring include quality
improvement, accountability, and identification of needs for
strategy adjustments and promotion of patient empowerment.
DISCUSSION AND CONCLUSIONS
ERN-RND provides an expertise-based infrastructure for sharing
knowledge and coordinating care for patients affected by RNDs.
The evolving network presents a new unique organization able
to create, take up, and implement emerging diagnostic, care, and
treatment innovations.
Built as a virtual network, ERN-RND provides–besides
the flagship CPMS–also e-solutions for all other areas of
cooperation of the different project bodies and stakeholders,
including webinars, cloud-based document-repositories, and
web conferences.
Future challenges include equity of quality of care being
provided across the EU as well as the systematic integration of
ERN into the national healthcare systems.
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